Literature DB >> 9556058

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

S P Luckman1, D E Hughes, F P Coxon, R Graham, G Russell, M J Rogers.   

Abstract

Bisphosphonates are currently the most important class of antiresorptive drugs used for the treatment of metabolic bone diseases. Although the molecular targets of bisphosphonates have not been identified, these compounds inhibit bone resorption by mechanisms that can lead to osteoclast apoptosis. Bisphosphonates also induce apoptosis in mouse J774 macrophages in vitro, probably by the same mechanisms that lead to osteoclast apoptosis. We have found that, in J774 macrophages, nitrogen-containing bisphosphonates (such as alendronate, ibandronate, and risedronate) inhibit post-translational modification (prenylation) of proteins, including the GTP-binding protein Ras, with farnesyl or geranylgeranyl isoprenoid groups. Clodronate did not inhibit protein prenylation. Mevastatin, an inhibitor of 3-hydroxy-3-methylglutatyl (HMG)-CoA reductase and hence the biosynthetic pathway required for the production of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, also caused apoptosis in J774 macrophages and murine osteoclasts in vitro. Furthermore, alendronate-induced apoptosis, like mevastatin-induced apoptosis, could be suppressed in J774 cells by the addition of farnesyl pyrophosphate or geranylgeranyl pyrophosphate, while the effect of alendronate on osteoclast number and bone resorption in murine calvariae in vitro could be overcome by the addition of mevalonic acid. These observations suggest that nitrogen-containing bisphosphonate drugs cause apoptosis following inhibition of post-translational prenylation of proteins such as Ras. It is likely that these potent antiresorptive bisphosphonates also inhibit bone resorption by preventing protein prenylation in osteoclasts and that enzymes of the mevalonate pathway or prenyl protein transferases are the molecular targets of the nitrogen-containing bisphosphonates. Furthermore, the data support the view that clodronate acts by a different mechanism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9556058     DOI: 10.1359/jbmr.1998.13.4.581

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  274 in total

Review 1.  Statins and bones.

Authors:  M H Moghadasian; J J Frohlich
Journal:  CMAJ       Date:  2001-03-20       Impact factor: 8.262

2.  Bisphosphonate-associated femur fractures have high complication rates with operative fixation.

Authors:  Mark L Prasarn; Jaimo Ahn; David L Helfet; Joseph M Lane; Dean G Lorich
Journal:  Clin Orthop Relat Res       Date:  2012-06-06       Impact factor: 4.176

3.  Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts.

Authors:  Joo-Young Ohe; Yong-Dae Kwon; Hyeon-Woo Lee
Journal:  Clin Oral Investig       Date:  2011-09-22       Impact factor: 3.573

4.  Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?

Authors:  Tilman Todenhöfer; Jörg Hennenlotter; Ursula Kühs; Valentina Gerber; Georgios Gakis; Ulrich Vogel; Stefan Aufderklamm; Axel Merseburger; Judith Knapp; Arnulf Stenzl; Christian Schwentner
Journal:  World J Urol       Date:  2012-03-11       Impact factor: 4.226

Review 5.  HMG CoA reductase inhibitors and the skeleton: a comprehensive review.

Authors:  D C Bauer
Journal:  Osteoporos Int       Date:  2003-05-08       Impact factor: 4.507

6.  Periprosthetic bone density as outcome of therapeutic response.

Authors:  Giovanni Iolascon; Gioconda Di Pietro; Annarita Capaldo; Carmine Gioia; Salvatore Gatto; Francesca Gimigliano
Journal:  Clin Cases Miner Bone Metab       Date:  2010-01

7.  BTN3A1 Discriminates γδ T Cell Phosphoantigens from Nonantigenic Small Molecules via a Conformational Sensor in Its B30.2 Domain.

Authors:  Mahboob Salim; Timothy J Knowles; Alfie T Baker; Martin S Davey; Mark Jeeves; Pooja Sridhar; John Wilkie; Carrie R Willcox; Hachemi Kadri; Taher E Taher; Pierre Vantourout; Adrian Hayday; Youcef Mehellou; Fiyaz Mohammed; Benjamin E Willcox
Journal:  ACS Chem Biol       Date:  2017-09-14       Impact factor: 5.100

8.  Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.

Authors:  Rafael Scaf de Molon; Simon Cheong; Olga Bezouglaia; Sarah M Dry; Flavia Pirih; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2014-08-02       Impact factor: 4.398

Review 9.  Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis.

Authors:  Christos Hatzigeorgiou; Jeffrey L Jackson
Journal:  Osteoporos Int       Date:  2005-03-03       Impact factor: 4.507

Review 10.  Statin therapy in the elderly: does it make good clinical and economic sense?

Authors:  Moira M B Mungall; Allan Gaw; James Shepherd
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.